Background Loss of donor-mediated immune antitumor activity after allogeneic
hematopoietic stem-cell transplantation (HSCT) permits relapse of hematologic cancers. We …

Ex vivo systems that incorporate features of the tumor microenvironment and model the
dynamic response to immune checkpoint blockade (ICB) may facilitate efforts in precision …

Cutaneous T cell lymphoma (CTCL) is a cancer of skin-homing T cells with variants that include
leukemic CTCL (L-CTCL), a malignancy of central memory T cells (T CM ), and mycosis …

More than 90% of drugs with preclinical activity fail in human trials, largely due to insufficient
efficacy. We hypothesized that adequately powered trials of patient-derived xenografts (PDX…

Expanding the US Food and Drug Administration–approved indications for immune checkpoint
inhibitors in patients with cancer has resulted in therapeutic success and immune-related …

Taxanes (docetaxel and paclitaxel) are among the most commonly prescribed anticancer
drugs approved for the treatment of metastatic or locally advanced breast, non-small cell lung, …

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematologic
malignancy with dismal outcomes for which no standard therapy exists. We found that primary …

Early diagnosis of cutaneous T cell lymphoma (CTCL) is difficult and takes on average 6
years after presentation, in part because the clinical appearance and histopathology of CTCL …

Importance Immune checkpoint inhibitors (ICIs) have emerged as active therapies for a
variety of cancers. Cutaneous toxicities are common immune-related adverse events and …

… Statistical analyses were performed with R, version 3.5.3 (R Core Team, Vienna, Austria). …
Drs Mostaghimi and LeBoeuf are cosenior authors. …